Larazotide: Research Profile, Dosages & Supplier Prices

GI / barrier research · Lyophilized powder · Also known as: AT-1001, Larazotide acetate

Larazotide is a gi / barrier research compound with a molecular weight of 725.8 g/mol and a research half-life of short; acts locally in the gi lumen. Larazotide (AT-1001) is an octapeptide derived from the zonula occludens toxin of Vibrio cholerae, developed as an oral tight-junction regulator. It is one of the few peptides designed to work locally in the gut lumen rather than systemically - it reduces intestinal permeability ('leaky gut') by modulating the tight junction proteins that seal the space between epithelial cells.

Research Use Only (RUO). Not for human or veterinary use. Not medical advice.

Sequence	H-Gly-Gly-Val-Leu-Val-Gln-Pro-Gly-OH
Formula	C32H55N9O10
Mol. weight	725.8 g/mol
Half-life	Short; acts locally in the GI lumen
Forms sold	Lyophilized powder

What is Larazotide?

Larazotide reached Phase 3 clinical trials for celiac disease, where it reduced gluten-triggered symptoms in several studies, and it remains the most clinically advanced tight-junction modulator. Research applications extend to intestinal barrier models in IBD, type 1 diabetes (where gut permeability is implicated), and liver disease. Because it acts locally and is minimally absorbed, its safety profile in trials was favorable - a key reason it progressed so far clinically.

Mechanism of Action (Research Context)

Modulates epithelial tight junctions by antagonizing zonulin-pathway disassembly of junctional complexes, reducing paracellular permeability. Acts locally within the GI lumen with minimal systemic absorption.

Research Areas

Intestinal barrier / tight junction regulationCeliac disease modelsIBD and leaky gut researchZonulin pathway pharmacology

Larazotide Dosages in Research

5mg10mg

Celiac trials used 0.25-8 mg oral doses before meals. Minimal systemic absorption by design. Research-context only.

Dosage information is a summary of published laboratory research and is provided for informational purposes only. These compounds are not for human use.

Storage & Handling

Lyophilized: -20C desiccated. Reconstituted: 2-8C, use within 2 weeks.

Larazotide Supplier Price Comparison

No tracked suppliers stock Larazotide yet — inventory syncs run continuously. Check our supplier reviews.

Larazotide FAQ

Intestinal permeability: it is a tight-junction regulator that reached Phase 3 trials in celiac disease, and is researched in IBD, type 1 diabetes and other conditions linked to barrier dysfunction.

Minimally - it is designed to act locally in the gut lumen on epithelial tight junctions, which contributed to its favorable safety profile in clinical trials.

98%+ HPLC purity and mass spec identity at 725.8 Da (free base; acetate salt will show the acetate counterion).

Age & Use Verification